CN100493516C - Clorfarabine composition - Google Patents
Clorfarabine composition Download PDFInfo
- Publication number
- CN100493516C CN100493516C CNB2006100454743A CN200610045474A CN100493516C CN 100493516 C CN100493516 C CN 100493516C CN B2006100454743 A CNB2006100454743 A CN B2006100454743A CN 200610045474 A CN200610045474 A CN 200610045474A CN 100493516 C CN100493516 C CN 100493516C
- Authority
- CN
- China
- Prior art keywords
- clofarabine
- composition
- tween
- weight
- cosolvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The present invention relates to medicine composition containing clofarabine, and is especially one kind of non-gastrointestinal tract administrated clofarabine composition. The clofarabine composition contains clinically effective clofarabine and pharmaceutically acceptable cosolvent niacinamide or meglumine in the weight ratio of 1 to 0.25-40. The clofarabine composition has high disslubility, high stability and other advantages.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that contains clofarabine (Clofarabine), specifically, relate to a kind of compositions that contains the parenteral canal drug administration of clofarabine.
Technical background
The chemistry of clofarabine is called 2-chloro-9-(2-deoxidation-2-fluoro-beta-D-arabinofuranosyl)-9H-purine-6-amine, and molecular formula is C
10H
11ClFN
5O
3, molecular weight is 303.68.Be second filial generation purine nucleosides analog derivative, it at first can effectively suppress ribonucleotide reductase after deoxycytidine kinase phosphoric acid turns to triphosphate, makes the synthetic termination of DNA; And can suppress archaeal dna polymerase a, the DNA chain is no longer prolonged.Clofarabine has cytotoxicity to multiple solid tumor, and is especially effective to acute leukemia.On December 29th, 2004, and the drugs approved by FDA clofarabine is used for the treatment of child's intractable or recurrent acute lymphoblastic leukemia (ALL).
Clofarabine is slightly soluble in water, and dissolubility is 1.5mg/ml in water, and its aqueous solution has microgranule and separates out in put procedure.The injection of U.S.'s listing does not have for the 20mg clofarabine is dissolved in 20mL in the normal saline of buffer (being made up of water for injection and sodium chloride).Before the venoclysis, need to use 0.2 μ m aseptic injection filter filtering liquid medicine, further dilute with 5% glucose injection or 0.9% sodium chloride injection then.This brings very big inconvenience to clinical practice.Therefore, how clofarabine is made the preparation with good solubility and stability is the problem that people attempt to solve always.
Summary of the invention
In order to overcome the deficiency of prior art, the object of the present invention is to provide a kind of compositions that contains the parenteral external administration of clofarabine, said composition has improved the dissolubility of clofarabine greatly, reduced liquor capacity, and steady quality, convenient transportation is convenient to clinical use.Also can adopt routine techniques that it is prepared into lyophilized powder or spray-dired powder, the back solution that redissolves is clear and bright, does not have microgranule.
Find to utilize consumption can not fully improve the dissolubility of clofarabine in water by testing us for 12.5 times of hydroxypropyl beta cyclodextrin enclose of agent clofarabine weight ratio; By adding conventional alkali compounds, as: sodium hydroxide, sodium hydrogen phosphate, sodium acetate, sodium carbonate, arginine etc., make its salify can improve the dissolubility of clofarabine in water, but can not guarantee that the clarity of solution is qualified after the freezing-thawing test, be that the cosolvent Tween 80 of 7.5 times of agent clofarabine weight ratios still can not obtain satisfied effect even further add consumption.Use to surpass 12.5 times of Tween 80s of agent clofarabine weight ratio, can improve solution clarity after the freezing-thawing test.But well-known, adopt intravenously administrable, the Tween 80 consumption is crossed conference and is caused haemolysis and anaphylaxis in the medicinal liquid.
Through deeply test, we find that nicotiamide and meglumine not only can improve the dissolubility of clofarabine in water, reduce quantity of solvent, but also make solution-stabilized after the preparation, can make the consumption of cosolvent Tween 80 reduce to the agent clofarabine weight ratio below 1.25 times, and stand the test of freezing-thawing test.Also can adopt routine techniques that it is prepared into lyophilized powder or spray-dired powder, the back solution that redissolves is clear and bright, does not have microgranule.
Correlation test the results are shown in following table.
The objective of the invention is to realize by following measure:
Clofarabine composition of the present invention contains the clofarabine and the pharmaceutically acceptable cosolvent of clinical effective dose, and described cosolvent is a nicotiamide; The part by weight of described clofarabine and cosolvent is 1:12.5-40.
Clofarabine composition of the present invention contains the clofarabine and the pharmaceutically acceptable cosolvent of clinical effective dose, and described cosolvent is nicotiamide and Tween 80; The part by weight of described clofarabine and nicotiamide is 1:0.25-40; The part by weight of described clofarabine and Tween 80 is 1:0.1-12.5.The preferred weight ratio of described clofarabine and Tween 80 is 1:0.5-1.25.
Compositions of the present invention can be made solution, lyophilized powder or spray-dired powder.
Compositions of the present invention can also add a certain amount of pharmaceutically acceptable excipient, and described clofarabine and excipient preferred weight ratio are 1:5-20; Described excipient is one or more in mannitol, low molecular dextran, lactose, sorbitol, glycine preferably.
The clofarabine composition that contains clinical effective dose of the present invention can make by the following method:
1. take by weighing the clofarabine adding or do not add Tween 80, mix homogeneously adds nicotiamide or meglumine, adds water (about 80 ℃) stirring and dissolving, adds or do not add excipient.
2. get the injection special-purpose activated charcoal and add in the above-mentioned solution liquid, stirred 20 minutes, filter fine straining.
3. with above-mentioned filled with solution.Or whole technology adopts common process lyophilization or spray drying under aseptic condition.
The invention has the beneficial effects as follows that prepared clofarabine composition has good dissolubility and stability, be convenient to transportation, store and use.And the production technology simple possible, can realize suitability for industrialized production.
The specific embodiment
Below will the invention will be further described by embodiment, these descriptions are not that content of the present invention is done further to limit.One skilled in the art will understand that to be equal to replacement to what content of the present invention was done, or corresponding the improvement, still belong within protection scope of the present invention.
Embodiment 1
Clofarabine 20mg
Nicotiamide 5mg
Tween 80 150mg
Mannitol 100mg
Water for injection adds to 10ml
Embodiment 2
Clofarabine 20mg
Nicotiamide 50mg
Tween 80 15mg
Mannitol 250mg
Water for injection adds to 5ml
Embodiment 3
Clofarabine 20mg
Nicotiamide 100mg
Tween 80 50mg
Dextran 40 250mg
Water for injection adds to 5ml
Embodiment 4
Clofarabine 20mg
Nicotiamide 150mg
Tween 80 100mg
Mannitol 250mg
Water for injection adds to 5ml
Embodiment 5
Clofarabine 20mg
Nicotiamide 250mg
Water for injection adds to 3ml
Embodiment 6
Clofarabine 20mg
Nicotiamide 500mg
Tween 80 10mg
Mannitol 200mg
Water for injection adds to 5ml
Embodiment 7
Clofarabine 20mg
Nicotiamide 800mg
Tween 80 30mg
Dextran 40 300mg
Water for injection adds to 10ml
Embodiment 1-7 compositions pH scope is 6.5-8.5.
Embodiment 8
Clofarabine 20mg
Meglumine 5mg
Tween 80 50mg
Mannitol 400mg
Water for injection adds to 10ml
Embodiment 9
Clofarabine 20mg
Meglumine 50mg
Mannitol 250mg
Water for injection adds to 5ml
Embodiment 10
Clofarabine 20mg
Meglumine 250mg
Mannitol 250mg
Water for injection adds to 3ml
Embodiment 11
Clofarabine 20mg
Meglumine 500mg
Water for injection adds to 15ml
Embodiment 12
Clofarabine 20mg
Meglumine 100mg
Tween 80 2mg
Mannitol 250mg
Water for injection adds to 5ml
Embodiment 7-12 preparation pH scope is 8.5-11.0.
The compositions of above-mentioned 1-12 embodiment is clear and bright aqueous solution after by aforementioned prepared, or through conventional technology lyophilization or spray drying, make lyophilized powder or spray-dired powder after, add 3-15ml water and redissolve, still obtain clear and bright aqueous solution.
Claims (7)
1, a kind of clofarabine composition is characterized in that: contain the clofarabine and the pharmaceutically acceptable cosolvent of clinical effective dose, described cosolvent is a nicotiamide; The part by weight of described clofarabine and cosolvent is 1:12.5-40.
2, compositions according to claim 1 is characterized in that: make solution, lyophilized powder or spray-dired powder.
3, compositions according to claim 1 is characterized in that: add a certain amount of pharmaceutically acceptable excipient, described clofarabine and excipient part by weight are 1:5-20; Described excipient is selected from one or more in mannitol, low molecular dextran, lactose, sorbitol, the glycine.
4, a kind of clofarabine composition is characterized in that: contain the clofarabine and the pharmaceutically acceptable cosolvent of clinical effective dose, described cosolvent is nicotiamide and Tween 80; The part by weight of described clofarabine and nicotiamide is 1:0.25-40; The part by weight of described clofarabine and Tween 80 is 1:0.1-12.5.
5, compositions according to claim 4 is characterized in that: the part by weight of described clofarabine and Tween 80 is 1:0.5-1.25.
6, according to claim 4 or 5 described compositionss, it is characterized in that: make solution, lyophilized powder or spray-dired powder.
7, according to claim 4 or 5 described compositionss, it is characterized in that: add a certain amount of pharmaceutically acceptable excipient, described clofarabine and excipient part by weight are 1:5-20; Described excipient is selected from one or more in mannitol, low molecular dextran, lactose, sorbitol, the glycine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100454743A CN100493516C (en) | 2006-07-12 | 2006-07-12 | Clorfarabine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100454743A CN100493516C (en) | 2006-07-12 | 2006-07-12 | Clorfarabine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1887291A CN1887291A (en) | 2007-01-03 |
| CN100493516C true CN100493516C (en) | 2009-06-03 |
Family
ID=37576571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100454743A Active CN100493516C (en) | 2006-07-12 | 2006-07-12 | Clorfarabine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100493516C (en) |
-
2006
- 2006-07-12 CN CNB2006100454743A patent/CN100493516C/en active Active
Non-Patent Citations (4)
| Title |
|---|
| 成人急性髓性白血病治疗新策略. 王斌等.世界临床药物，第27卷第5期. 2006 |
| 成人急性髓性白血病治疗新策略. 王斌等.世界临床药物，第27卷第5期. 2006 * |
| 药剂学. 毕殿洲，241，人民卫生出版社. 2001 |
| 药剂学. 毕殿洲，241，人民卫生出版社. 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1887291A (en) | 2007-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2620341C2 (en) | Stabilized pemetrexed composition | |
| JP6869941B2 (en) | A method for producing a lyophilized pharmaceutical composition having a certain content of mitomycin C. | |
| WO2006046079A1 (en) | Formulations comprising ecteinascidin and a disaccharide | |
| JP2009538294A (en) | Pharmaceutical composition containing docetaxel having stability, and method for producing the same | |
| WO2019006741A1 (en) | Preparation of pulsatilla saponin b4 for injection | |
| CN103159769A (en) | Doxofylline compound and medicine composition thereof | |
| CN102525963B (en) | Netilmicin sulfate lyophiled powder injection and preparation method thereof | |
| CN100493516C (en) | Clorfarabine composition | |
| CN101088492B (en) | Stable supersaturated gemcitabine hydrochloride solution and its preparation process | |
| WO2016005995A2 (en) | Glycol free stable liquid compositions of bendamustine | |
| CN101254174B (en) | Freeze-dried injection containing carbazochrome sodium sulfonate and method of preparing the same | |
| CN103980279B (en) | A kind of methotrexate compound and methotrexate for injection | |
| CN100406021C (en) | Breviscapine B injection preparation and its preparing method | |
| CN102274185A (en) | Antitumor pH-sensitive liposome and freeze-dried powder injection thereof, and preparation methods thereof | |
| CN104666253B (en) | Clindamycin phosphate powder for injection pharmaceutical composition and preparation method | |
| CN109820820B (en) | Alprostadil injection and preparation method thereof | |
| CN109828046B (en) | Detection method of alprostadil injection | |
| CN102743342A (en) | Sodium fusidate lyophilized composition for injection | |
| CN106853252B (en) | Trabectedin pharmaceutical composition and preparation method thereof | |
| CN108289897B (en) | Pharmaceutical composition of remazolam | |
| CN1271996C (en) | Medicinal powder injection for respiratory system and preparing method | |
| CN110934875A (en) | 5-fluorouracil methotrexate double-drug preparation and preparation method thereof | |
| CN102144979B (en) | frozen powder preparation for injection of L-gossypol or acetate of L-gossypol for treatment of tumor | |
| CN103536541B (en) | Clarithromycin freeze-dried injection and preparation method thereof | |
| CN100477998C (en) | Instant pyrobixi freeze-drying powdery injection and its production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 250000 Ji'nan, Shandong hi tech Zone, East China Road century wealth center C block, 201 Patentee after: SHANDONG BESTCOMM PHARMACEUTICAL CO., LTD. Address before: 250013, No. 11, mountain road, Licheng District, Shandong, Ji'nan Patentee before: Bainuo Medicines Development Co., Ltd., Jinan |